Daewoong Pharmaceutical obtains Chinese product approval for Pexuclu, a treatment for gastroesophageal reflux disease
Sep 05, 2025
|
Pexuclu is a third-generation gastroesophageal reflux disease treatment of the P-CAB (potassium competitive gastric acid secretion inhibitor) family launched by Daewoong Pharmaceutical in 2022. It is expected to quickly increase its market share in the Chinese anti-arche drug market by improving the slow onset of drug effects, short half-life, and shortcomings of pre-meal use, which are considered disadvantages of existing PPI drugs (proton pump inhibitors).
Starting with the release of Pexuklu in the second half of 2026, Daewoong Pharmaceutical plans to implement its entry strategy in earnest by reflecting the characteristics and demand of China.
According to IMS data, a global market research firm, China's anti-rheumatic market is about 3 trillion won as of last year, the largest in the world. In particular, the number of patients with gastroesophageal reflux disease is rapidly increasing due to recent changes in westernized eating habits of 1.4 billion people, which is expected to expand demand for treatment.
Meanwhile, Pexuclu is rapidly growing into a blockbuster drug, exceeding 100 billion won in annual sales at home and abroad three years after its launch as of last year. Currently, it has been released in six countries, including India, Mexico, Chile, Ecuador, and the Philippines, and China, Panama, and Colombia have been approved and are preparing to be released. Pexuklu has now entered a total of 30 countries and aims to enter 100 countries by 2027.
Park Sung-soo, CEO of Daewoong Pharmaceutical, said, "This Chinese product approval will be a very important turning point in Pexuclu's leap into a global blockbuster drug. We will do our best to establish Pexuclu as the most trusted treatment option for patients and medical staff in China, the world's largest anti-arousal drug market."."
This article was translated by Naver AI translator.
